Loading clinical trials...

The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma | Clinical Trials | Clareo Health

COMPLETEDPHASE4

The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma

NCT01908972•Seoul National University Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the safety and efficiency of Propranolol as an initial treatment for pediatric hemangioma.

Detailed Description

* Randomized (A group : propranolol, B group : prednisolone) * A group : 3 days admission and medication for 16 weeks * B group : medication for 16 weeks without admission * Hemangioma volume comparison by using MRI * other measurement and drug adverse reaction monitoring

Eligibility

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Hemangioma patient ( 0 \~ 9 months old)
•No treatment before
•10 \~ 20 % volume increase in 2 \~ 4 weeks
•Hemangioma that caused organ function
•Hemangioma that will cause aesthetic problem

Exclusion Criteria

•Cardiovascular disease (impossible to use propranolol)
•Drug adverse reaction or allergy history (propranolol, steroid)
•Bradycardia, Atrioventricular block, atrial block
•Cardiogenic Shock
•Right heart failure (pulmonary hypertension)
•Congestive heart failure
•Hypotension
•Peripheral nerve disease (moderate)
•Angina
•Hormone deficiency patient
+3 more criteria

Locations (1)

Seould National University Hospital

Seoul, South Korea

Key Dates

Start Date

June 1, 2013

Primary Completion Date

May 1, 2015

Completion Date

May 1, 2015

Last Updated

December 19, 2018

Enrollment

ACTUAL participants

Conditions

Hemangioma

Interventions

Prednisolone

DRUG

Propranolol

DRUG

Fluctuational Imaging for the Diagnosis of Hepatic Hemangioma: A Multicenter, Prospective Study

NCT07418294

Hemangioma

View study

RECRUITINGNA

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn

NCT01873131

Hemangioma

View study

ACTIVE_NOT_RECRUITING

Modifiers of Disease Severity in Cerebral Cavernous Malformations

NCT01764529

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma

Inclusion Criteria

Exclusion Criteria

Fluctuational Imaging for the Diagnosis of Hepatic Hemangioma: A Multicenter, Prospective Study

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn

Modifiers of Disease Severity in Cerebral Cavernous Malformations

A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures

Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma

The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma